Frazier Life Sciences Public Fund, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Maze Therapeutics, Inc. Common Stock - par value $0.001 per share (MAZE)

Filing Manager
Frazier Life Sciences Public Fund, L.P.
Reporting Manager
Frazier Life Sciences Public Fund, L.P.
Security
Maze Therapeutics, Inc. Common Stock - par value $0.001 per share
Symbol
MAZE
Shares outstanding
48,247,400 shares
Disclosed Ownership
4,342,266 shares
Ownership
9%
Form type
SCHEDULE 13G/A
Filing time
13 Feb 2026, 17:31:06 UTC
Date of event
31 Dec 2025
Previous filing
14 Aug 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Frazier Life Sciences Public Fund, L.P. disclosed 9% ownership in Maze Therapeutics, Inc. Common Stock - par value $0.001 per share (MAZE) on 31 Dec 2025."

Quick Takeaways

  • Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G/A for Maze Therapeutics, Inc. Common Stock - par value $0.001 per share (MAZE).
  • Disclosed ownership: 9%.
  • Date of event: 31 Dec 2025.

What Changed

  • Previous schedule filing date: 14 Aug 2025.
  • Current filing was accepted on 13 Feb 2026, 17:31.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (14)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Frazier Life Sciences Public Fund, L.P. 9% 4,342,266 0 4,342,266 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
FHMLSP, L.P. 9% 4,342,266 0 4,342,266 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
FHMLSP, L.L.C. 9% 4,342,266 0 4,342,266 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLSP, L.L.C.
Frazier Life Sciences X, L.P. 0.2% 75,982 0 75,982 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
FHMLS X, L.P. 0.2% 75,982 0 75,982 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
FHMLS X, L.L.C. 0.2% 75,982 0 75,982 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. 0.3% 149,026 0 149,026 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
FHMLS XI, L.P. 0.3% 149,026 0 149,026 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
FHMLS XI, L.L.C. 0.3% 149,026 0 149,026 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. 0% 0 0 0 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
FHMLS XII, L.P. 0% 0 0 0 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
FHMLS XII, L.L.C. 0% 0 0 0 /s/ Jennifer Martin By Jennifer Martin, CFO of FHMLS XII, L.L.C.
James N. Topper 0.2% 75,982 0 75,982 /s/ Jennifer Martin By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026
Patrick J. Heron 0.2% 75,982 0 75,982 /s/ Jennifer Martin By Jennifer Martin, Attorney-in-Fact for Patrick Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026

Sponsored